Company: Opko Health
Drug Type: Small Molecule
Conditions: Parkinson’s disease
Mechanism Type: Neuroprotection
Mechanism: SR3306 is an orally bioavailable, aminopyrimidine inhibitor of c-Jun N-terminal kinases (JNKs), a class of mitogen-activated protein kinases (MAPK) that respond to conditions of stress and regulate neuronal survival. The compound is orally available and CNS penetrant according to studies in animal models, as well as protects neurons in two animal models of Parkinson’s disease. The mechanism of action is potentially relevant to ALS due to a evidence for link between JNK activation and TDP-43 toxicity.
U.S. Status for ALS: N/A
 JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease. Crocker, C et al. ACS Chem Neurosci. 2011 Apr 20;2(4):207-212.
 The JNK/c-Jun signaling axis contributes to the TDP-43-induced cell death. Suzuki, H, Matsuoka, M. Mol Cell Biochem. 2013 Jan;372(1-2):241-8.
Last updated March 11th, 2019